These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33638886)

  • 1. MiRNAs and radical prostatectomy: Current data, bioinformatic analysis and utility as predictors of tumour relapse.
    Konoshenko MY; Laktionov PP
    Andrology; 2021 Jul; 9(4):1092-1107. PubMed ID: 33638886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
    PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?
    Zhao Z; Stephan C; Weickmann S; Jung M; Kristiansen G; Jung K
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28934131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles.
    Shutko EV; Bryzgunova OE; Murina EA; Ostaltcev IA; Krasilnikov SE; Laktionov PP; Konoshenko MY
    Urol Oncol; 2024 Nov; 42(11):371.e19-371.e30. PubMed ID: 39107171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miRNAs and radiotherapy response in prostate cancer.
    Konoshenko MY; Bryzgunova OE; Laktionov PP
    Andrology; 2021 Mar; 9(2):529-545. PubMed ID: 33053272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The miRNAs involved in prostate cancer chemotherapy response as chemoresistance and chemosensitivity predictors.
    Konoshenko M; Laktionov P
    Andrology; 2022 Jan; 10(1):51-71. PubMed ID: 34333834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.
    Strand SH; Bavafaye-Haghighi E; Kristensen H; Rasmussen AK; Hoyer S; Borre M; Mouritzen P; Besenbacher S; Orntoft TF; Sorensen KD
    Int J Cancer; 2019 Dec; 145(12):3445-3452. PubMed ID: 31125115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer therapy outcome prediction: are miRNAs a suitable guide for therapeutic decisions?
    Konoshenko M; Laktionov P; Bryzgunova O
    Andrology; 2024 May; 12(4):705-718. PubMed ID: 37750354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    Zedan AH; Blavnsfeldt SG; Hansen TF; Nielsen BS; Marcussen N; Pleckaitis M; Osther PJS; Sørensen FB
    PLoS One; 2017; 12(6):e0179113. PubMed ID: 28628624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microRNAs in plasma before and after radical prostatectomy.
    McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
    Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
    Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
    Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.
    Fendler A; Jung M; Stephan C; Honey RJ; Stewart RJ; Pace KT; Erbersdobler A; Samaan S; Jung K; Yousef GM
    Int J Oncol; 2011 Nov; 39(5):1183-92. PubMed ID: 21769427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
    Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
    Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
    Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
    Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
    Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
    Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
    Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
    BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.